Home » Stocks » EPZM

Epizyme, Inc. (EPZM)

Stock Price: $11.81 USD 0.09 (0.72%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
After-hours: $11.75 -0.06 (-0.51%) Jan 19, 6:24 PM
Market Cap 1.18B
Revenue (ttm) 11.68M
Net Income (ttm) -221.86M
Shares Out 101.51M
EPS (ttm) -2.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $11.81
Previous Close $11.73
Change ($) 0.09
Change (%) 0.72%
Day's Open 11.84
Day's Range 11.48 - 11.99
Day's Volume 521,092
52-Week Range 10.34 - 26.72

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 month ago

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme to Participate in Jefferies Virtual London Healthcare Conference

Zacks Investment Research - 2 months ago

Epizyme (EPZM) reports a narrower-than-expected loss and misses sales estimates in the third quarter of 2020.

Seeking Alpha - 2 months ago

Epizyme, Inc. (EPZM) CEO Robert Bazemore on Q3 2020 Results - Earnings Call Transcript

Benzinga - 2 months ago

Shares of Epizyme (NASDAQ:EPZM) remained unaffected after the company reported Q3 results.

Zacks Investment Research - 2 months ago

Epizyme (EPZM) delivered earnings and revenue surprises of 9.84% and -40.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today provided ...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced...

Zacks Investment Research - 2 months ago

Epizyme (EPZM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme Announces Two Lancet Oncology Publications on TAZVERIK® (tazemetostat) Phase 2 Data in Epithelioid Sarcoma and Follicular Lymphoma

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc.

Zacks Investment Research - 4 months ago

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 5 months ago

Epizyme (EPZM) reports a wider-than-expected loss and misses sales estimates in the second quarter of 2020.

Seeking Alpha - 5 months ago

Epizyme's (EPZM) CEO Rob Bazemore on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Epizyme (EPZM) delivered earnings and revenue surprises of -3.57% and -47.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme Reports Business Progress and Second Quarter 2020 Financial Results

Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc.

Seeking Alpha - 6 months ago

Epizyme A Buy For Tazverik And Epigenetic Platform

Benzinga - 6 months ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit.

Other stocks mentioned: CLR, FOX, GRPN, AXS, CATM, ED, RPRX, VST, WSBC
Zacks Investment Research - 7 months ago

The FDA grants approval to Epizyme's (EPZM) sNDA for lead drug,Tazverik, for two distinct follicular lymphoma indications.

Zacks Investment Research - 7 months ago

Investors need to pay close attention to Epizyme (EPZM) stock based on the movements in the options market lately.

Market Watch - 7 months ago

Shares of Epizyme Inc. EPZM, +4.81% were down 2.3% in premarket trading on Friday, the day after it said the Food and Drug Administration had approved Tazverik as a treatment for relapsed or r...

The Motley Fool - 7 months ago

The label expansion for the drug significantly increases the number of patients to whom it can be prescribed.

The Motley Fool - 7 months ago

If you have cash to spare, these cancer stocks are set to soar.

Other stocks mentioned: GTHX
Zacks Investment Research - 7 months ago

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?

Seeking Alpha - 7 months ago

Epizyme, Inc. Is Doing Everything Right But Its Shares Appear Fairly Priced

Zacks Investment Research - 8 months ago

Epizyme (EPZM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 8 months ago

Epizyme (EPZM) reports a narrower-than-expected Q1 loss but misses on revenues.

Seeking Alpha - 8 months ago

Epizyme, Inc. (EPZM) CEO Rob Bazemore on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Epizyme (EPZM) delivered earnings and revenue surprises of 31.08% and -48.60%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 8 months ago

  Shares of Epizyme (NASDAQ:EPZM) were unaffected at $15.75 after the company reported Q1 results.

Zacks Investment Research - 8 months ago

Epizyme (EPZM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 9 months ago

These companies scored recent drug approvals. It's worth looking into their stocks to see if they're a buy now.

Other stocks mentioned: AIMT, ESPR, HZNP
The Motley Fool - 9 months ago

Investors were looking forward to the drug company's transition to commercial operations, but the coronavirus pandemic could delay the maturation process.

Zacks Investment Research - 9 months ago

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?

The Motley Fool - 10 months ago

Cancer is one of the most competitive -- and lucrative -- areas for biotech investors.

Other stocks mentioned: EXEL, IMMU
The Motley Fool - 10 months ago

On the heels of an FDA approval and with another due soon, investors may want to participate in a biotech that boasts It's

Other stocks mentioned: BMY, GSK
Zacks Investment Research - 10 months ago

Epizyme (EPZM) reports wider-than-expected loss in the fourth quarter of 2019. Nonetheless, its sales beat estimates.

Seeking Alpha - 10 months ago

Epizyme Inc. (EPZM) CEO Rob Bazemore on Q4 2019 Results - Earnings Call Transcript

The Motley Fool - 10 months ago

The pharma company released full-year 2019 operating results.

Zacks Investment Research - 10 months ago

Epizyme (EPZM) delivered earnings and revenue surprises of -15.69% and 51.57%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

We expect Epizyme (EPZM) to provide commercialization updates on its sarcoma drug when it releases fourth-quarter 2019 earnings.

Seeking Alpha - 11 months ago

Epizyme's NDA Accepted, And Other News: The Good, Bad And Ugly Of Biopharma

The Motley Fool - 11 months ago

Tazemetostat is already approved to treat advanced epithelioid sarcoma; the biotech is now pursing an approval for advanced follicular lymphoma.

Zacks Investment Research - 11 months ago

Epizyme (EPZM) closed at $21.78 in the latest trading session, marking a -0.5% move from the prior day.

Zacks Investment Research - 11 months ago

In the latest trading session, Epizyme (EPZM) closed at $20.93, marking a -1.83% move from the previous day.

Seeking Alpha - 11 months ago

Epizyme's Tazemetostat Is Approved, And Other News: The Good, Bad, And Ugly Of Biopharma

Seeking Alpha - 11 months ago

Epizyme Has One FDA Approval Down, One More To Go In Coming Months

The Motley Fool - 11 months ago

The biotech's FDA approval was priced in, but the company still has potential.

About EPZM

Epizyme, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma epithelioid sarcoma in the United States. It also develops Tazemetostat in combination with rituximab in patients with relapsed and refractory follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with p... [Read more...]

Industry
Biotechnology
IPO Date
May 31, 2013
CEO
Robert Bazemore
Employees
203
Stock Exchange
NASDAQ
Ticker Symbol
EPZM
Full Company Profile

Financial Performance

In 2019, Epizyme's revenue was $23.80 million, an increase of 9.68% compared to the previous year's $21.70 million. Losses were -$170.30 million, 37.7% more than in 2018.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for Epizyme stock is "Buy." The 12-month stock price forecast is 23.00, which is an increase of 94.75% from the latest price.

Price Target
$23.00
(94.75% upside)
Analyst Consensus: Buy